EGFR and adenocarcinoma: When qualifying patients diagnosed with adenocarcinoma and unspecified NSCLC for treatment with EGFR tyrosine kinase inhibitors, the presence of clinically relevant primary EGFR gene mutations (activating and responsible for resistance), which de novo occur in 10–15%, respectively, should be assessed in the available material and 1% of patients.